adplus-dvertising
Connect with us

News

Alberta feed stores inundated with calls for ivermectin over false claims livestock dewormer treats COVID – CBC.ca

Published

 on


Alberta feed stores say they’re receiving a deluge of callers asking to buy ivermectin due to misinformation that suggests the livestock dewormer can be used to treat COVID-19 in humans.

Lance Olson, manager of Lone Star Tack & Feed Inc., located just outside of Calgary, said false claims circulating about the animal medication have brought the wrong kind of attention to his business.

  • Have a coronavirus question or news tip for CBC News? Email: Covid@cbc.ca

“It’s obviously not intended for human use in any way, shape or form. It’s meant to get rid of worms in horses’ guts … so, these people see that ivermectin liquid, they search it, our website comes up and they give us a call thinking that we can just sell it to them,” Olson said.

“If you don’t know what it is, you probably don’t have animals that you’re going to use this on … given the circumstances surrounding this stuff, it makes it very uncomfortable when people phone … so we’ve taken it off our shelves.”

WATCH | Horse medication ineffective against COVID-19, says specialist:

Horse medication ineffective against COVID-19, says specialist

3 hours ago

Epidemiologist Dr. Christopher Labos says getting vaccinated is a safer and better way to protect against the coronavirus. (Benoit Tessier/Reuters) 1:10

Different forms of ivermectin are used to treat parasites, such as intestinal worms or lice, in both animals and humans.

The form of the drug used on humans is actually on the World Health Organization’s list of essential medicines because it is safe, inexpensive and effective — and has proven to be life-saving for treating some illnesses caused by parasites.

But, for multiple reasons, the livestock form of the drug should never be used on humans. One reason being that it is dosed for much larger organisms. Also, parasites are not the same as viruses. COVID-19 is caused by a virus. 

Touted as possible cure 

The largest study in favour of ivermectin as a COVID-19 treatment was retracted after concerns about data fabrication, plagiarism and ethical breaches. 

Medical journal The Lancet has called for more study on ivermectin’s efficacy to reduce viral load or improve recovery, but said there is no drug that can replace preventative public health policies and large-scale testing for COVID.

No clinical studies have proven yet whether ivermectin can slow or stop the novel coronavirus from growing in human cells — but that hasn’t stopped right-wing media personalities and politicians from touting it as a possible treatment or cure for COVID-19.

These flyers promoting misinformation that claims ivermectin is a treatment for COVID-19 were passed out in Banff, Alta., this week. Feed store owners in southern Alberta say they have received many calls from shoppers attempting to buy livestock dewormer for human consumption. (Andrew Thullier)

In May, Calgary mayoral candidate Kevin J. Johnston — a leader in the COVID-19 denial movement who was recently described by a judge as “dangerous and out of control” when he pleaded guilty to criminal charges — suggested that people visit farm supply stores to buy livestock ivermectin.

Derek Sloan, a controversial Ontario MP who was booted from the Conservative caucus and who is now running in the riding of Banff-Airdrie as an Independent for the upcoming federal election, has described ivermectin as a promising medicine during campaign stops and during debate in the House of Commons.

Former Alberta politician and talk radio host Danielle Smith, who previously falsely claimed that hydroxychloroquine cures COVID-19 (it doesn’t), suggested in a recent newsletter that information about ivermectin is being suppressed by Alberta Health Services (AHS) and the College of Physicians and Surgeons.

AHS says its scientific advisory group has conducted a review to explore using ivermectin; the drug is not approved to treat COVID-19 in the province.

The group advises against taking ivermectin as a COVID-19 treatment outside of clinical trials.

CBC News spoke with staff at two other feed stores in the Calgary area who confirmed they have been receiving multiple calls about ivermectin each week for months. CBC has agreed not to name the stores out of concern it could impact their business.

One store said at its peak it was receiving requests for one to two online orders per day from out of province, many to downtown Vancouver.

Don’t put things that aren’t tested on humans into yourself. It’s not worth it.– Lance Olson, manager of a Calgary-area feed supply store

Olson said in recent months his feed store’s website has received thousands of searches for ivermectin, nearly seven times as many searches as for the company’s name. 

In Alberta, a premises identification number is required for livestock owners to buy animal medications such as ivermectin. But Olson, and another store’s employee, said shoppers still attempt to circumvent that rule. 

“Don’t put it in your body,” Olson said. “Don’t put things that aren’t tested on humans into yourself. It’s not worth it. And obviously, the studies are not there yet. So just leave it alone.”

In the U.S., the Centers for Disease Control warned the public after increased calls to poison centres with reports of severe illness caused by the medicine. In Georgia, a police officer who took ivermectin for livestock instead of getting vaccinated died of COVID-19, according to a report from Insider. 

Feed stores aren’t the only place people are trying to acquire the veterinary medicine.

Dozens of social media posts appear to show Albertans attempting to or successfully acquiring ivermectin from online stores such as Amazon. CBC News has reached out to Amazon Canada to ask if it intends to continue to offer the product and if it will apply a warning label to those listings. 

If taken improperly, ivermectin can cause vomiting, diarrhea, low blood pressure, allergic reactions, seizures or even death, according to the U.S. FDA. 

Surgeon says patients requesting drug, too

Dr. Michael Chatenay, a general surgeon at Grey Nuns hospital in Edmonton, said last week he treated a COVID-positive patient who asked for ivermectin.

“I was, to be honest, shocked but not surprised because the conspiracy theory websites and social media have been abuzz with this crazy theory,” Chatenay said. “We just tell them that there’s no proven benefit.”

Chatenay said shortly after, another patient made the same request of one of his colleagues.

“It’s worrying,” he said. “For people that are already scared, or are worried about getting vaccinated, they’re looking for and grasping on to these treatments that could potentially be harmful.”

Chatenay said the greatest preventative measure for COVID-19 continues to be vaccination.

Alberta is experiencing a surging fourth wave with nearly 10,000 active cases and a positivity rate over 10 per cent, but just 59 per cent of the province’s total population is fully vaccinated. 

“I always try to emphasize that the safest and most well-studied method of preventing COVID infection is vaccination … not only does it help prevent infection, but it helps to reduce your chance of getting severely ill, being hospitalized, being sent to ICU or dying from COVID.”

Adblock test (Why?)

728x90x4

Source link

Continue Reading

News

STD epidemic slows as new syphilis and gonorrhea cases fall in US

Published

 on

 

NEW YORK (AP) — The U.S. syphilis epidemic slowed dramatically last year, gonorrhea cases fell and chlamydia cases remained below prepandemic levels, according to federal data released Tuesday.

The numbers represented some good news about sexually transmitted diseases, which experienced some alarming increases in past years due to declining condom use, inadequate sex education, and reduced testing and treatment when the COVID-19 pandemic hit.

Last year, cases of the most infectious stages of syphilis fell 10% from the year before — the first substantial decline in more than two decades. Gonorrhea cases dropped 7%, marking a second straight year of decline and bringing the number below what it was in 2019.

“I’m encouraged, and it’s been a long time since I felt that way” about the nation’s epidemic of sexually transmitted infections, said the CDC’s Dr. Jonathan Mermin. “Something is working.”

More than 2.4 million cases of syphilis, gonorrhea and chlamydia were diagnosed and reported last year — 1.6 million cases of chlamydia, 600,000 of gonorrhea, and more than 209,000 of syphilis.

Syphilis is a particular concern. For centuries, it was a common but feared infection that could deform the body and end in death. New cases plummeted in the U.S. starting in the 1940s when infection-fighting antibiotics became widely available, and they trended down for a half century after that. By 2002, however, cases began rising again, with men who have sex with other men being disproportionately affected.

The new report found cases of syphilis in their early, most infectious stages dropped 13% among gay and bisexual men. It was the first such drop since the agency began reporting data for that group in the mid-2000s.

However, there was a 12% increase in the rate of cases of unknown- or later-stage syphilis — a reflection of people infected years ago.

Cases of syphilis in newborns, passed on from infected mothers, also rose. There were nearly 4,000 cases, including 279 stillbirths and infant deaths.

“This means pregnant women are not being tested often enough,” said Dr. Jeffrey Klausner, a professor of medicine at the University of Southern California.

What caused some of the STD trends to improve? Several experts say one contributor is the growing use of an antibiotic as a “morning-after pill.” Studies have shown that taking doxycycline within 72 hours of unprotected sex cuts the risk of developing syphilis, gonorrhea and chlamydia.

In June, the CDC started recommending doxycycline as a morning-after pill, specifically for gay and bisexual men and transgender women who recently had an STD diagnosis. But health departments and organizations in some cities had been giving the pills to people for a couple years.

Some experts believe that the 2022 mpox outbreak — which mainly hit gay and bisexual men — may have had a lingering effect on sexual behavior in 2023, or at least on people’s willingness to get tested when strange sores appeared.

Another factor may have been an increase in the number of health workers testing people for infections, doing contact tracing and connecting people to treatment. Congress gave $1.2 billion to expand the workforce over five years, including $600 million to states, cities and territories that get STD prevention funding from CDC.

Last year had the “most activity with that funding throughout the U.S.,” said David Harvey, executive director of the National Coalition of STD Directors.

However, Congress ended the funds early as a part of last year’s debt ceiling deal, cutting off $400 million. Some people already have lost their jobs, said a spokeswoman for Harvey’s organization.

Still, Harvey said he had reasons for optimism, including the growing use of doxycycline and a push for at-home STD test kits.

Also, there are reasons to think the next presidential administration could get behind STD prevention. In 2019, then-President Donald Trump announced a campaign to “eliminate” the U.S. HIV epidemic by 2030. (Federal health officials later clarified that the actual goal was a huge reduction in new infections — fewer than 3,000 a year.)

There were nearly 32,000 new HIV infections in 2022, the CDC estimates. But a boost in public health funding for HIV could also also help bring down other sexually transmitted infections, experts said.

“When the government puts in resources, puts in money, we see declines in STDs,” Klausner said.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Source link

Continue Reading

News

World’s largest active volcano Mauna Loa showed telltale warning signs before erupting in 2022

Published

 on

 

WASHINGTON (AP) — Scientists can’t know precisely when a volcano is about to erupt, but they can sometimes pick up telltale signs.

That happened two years ago with the world’s largest active volcano. About two months before Mauna Loa spewed rivers of glowing orange molten lava, geologists detected small earthquakes nearby and other signs, and they warned residents on Hawaii‘s Big Island.

Now a study of the volcano’s lava confirms their timeline for when the molten rock below was on the move.

“Volcanoes are tricky because we don’t get to watch directly what’s happening inside – we have to look for other signs,” said Erik Klemetti Gonzalez, a volcano expert at Denison University, who was not involved in the study.

Upswelling ground and increased earthquake activity near the volcano resulted from magma rising from lower levels of Earth’s crust to fill chambers beneath the volcano, said Kendra Lynn, a research geologist at the Hawaiian Volcano Observatory and co-author of a new study in Nature Communications.

When pressure was high enough, the magma broke through brittle surface rock and became lava – and the eruption began in late November 2022. Later, researchers collected samples of volcanic rock for analysis.

The chemical makeup of certain crystals within the lava indicated that around 70 days before the eruption, large quantities of molten rock had moved from around 1.9 miles (3 kilometers) to 3 miles (5 kilometers) under the summit to a mile (2 kilometers) or less beneath, the study found. This matched the timeline the geologists had observed with other signs.

The last time Mauna Loa erupted was in 1984. Most of the U.S. volcanoes that scientists consider to be active are found in Hawaii, Alaska and the West Coast.

Worldwide, around 585 volcanoes are considered active.

Scientists can’t predict eruptions, but they can make a “forecast,” said Ben Andrews, who heads the global volcano program at the Smithsonian Institution and who was not involved in the study.

Andrews compared volcano forecasts to weather forecasts – informed “probabilities” that an event will occur. And better data about the past behavior of specific volcanos can help researchers finetune forecasts of future activity, experts say.

(asterisk)We can look for similar patterns in the future and expect that there’s a higher probability of conditions for an eruption happening,” said Klemetti Gonzalez.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

News

Waymo’s robotaxis now open to anyone who wants a driverless ride in Los Angeles

Published

 on

 

Waymo on Tuesday opened its robotaxi service to anyone who wants a ride around Los Angeles, marking another milestone in the evolution of self-driving car technology since the company began as a secret project at Google 15 years ago.

The expansion comes eight months after Waymo began offering rides in Los Angeles to a limited group of passengers chosen from a waiting list that had ballooned to more than 300,000 people. Now, anyone with the Waymo One smartphone app will be able to request a ride around an 80-square-mile (129-square-kilometer) territory spanning the second largest U.S. city.

After Waymo received approval from California regulators to charge for rides 15 months ago, the company initially chose to launch its operations in San Francisco before offering a limited service in Los Angeles.

Before deciding to compete against conventional ride-hailing pioneers Uber and Lyft in California, Waymo unleashed its robotaxis in Phoenix in 2020 and has been steadily extending the reach of its service in that Arizona city ever since.

Driverless rides are proving to be more than just a novelty. Waymo says it now transports more than 50,000 weekly passengers in its robotaxis, a volume of business numbers that helped the company recently raise $5.6 billion from its corporate parent Alphabet and a list of other investors that included venture capital firm Andreesen Horowitz and financial management firm T. Rowe Price.

“Our service has matured quickly and our riders are embracing the many benefits of fully autonomous driving,” Waymo co-CEO Tekedra Mawakana said in a blog post.

Despite its inroads, Waymo is still believed to be losing money. Although Alphabet doesn’t disclose Waymo’s financial results, the robotaxi is a major part of an “Other Bets” division that had suffered an operating loss of $3.3 billion through the first nine months of this year, down from a setback of $4.2 billion at the same time last year.

But Waymo has come a long way since Google began working on self-driving cars in 2009 as part of project “Chauffeur.” Since its 2016 spinoff from Google, Waymo has established itself as the clear leader in a robotaxi industry that’s getting more congested.

Electric auto pioneer Tesla is aiming to launch a rival “Cybercab” service by 2026, although its CEO Elon Musk said he hopes the company can get the required regulatory clearances to operate in Texas and California by next year.

Tesla’s projected timeline for competing against Waymo has been met with skepticism because Musk has made unfulfilled promises about the company’s self-driving car technology for nearly a decade.

Meanwhile, Waymo’s robotaxis have driven more than 20 million fully autonomous miles and provided more than 2 million rides to passengers without encountering a serious accident that resulted in its operations being sidelined.

That safety record is a stark contrast to one of its early rivals, Cruise, a robotaxi service owned by General Motors. Cruise’s California license was suspended last year after one of its driverless cars in San Francisco dragged a jaywalking pedestrian who had been struck by a different car driven by a human.

Cruise is now trying to rebound by joining forces with Uber to make some of its services available next year in U.S. cities that still haven’t been announced. But Waymo also has forged a similar alliance with Uber to dispatch its robotaxi in Atlanta and Austin, Texas next year.

Another robotaxi service, Amazon’s Zoox, is hoping to begin offering driverless rides to the general public in Las Vegas at some point next year before also launching in San Francisco.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending